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Several types of myeloid suppressor cell are currently being developed as cell-based immunosuppressive agents.
Despite detailed knowledge about the molecular and cellular functions of these cell types, expert opinions differ on
how to best implement such therapies in solid organ transplantation. Efforts in our laboratory to develop a
cell-based medicinal product for promoting tolerance in renal transplant patients have focused on a type of
suppressor macrophage, which we call the regulatory macrophage (M reg). Our favoured clinical strategy is to
administer donor-derived M regs to recipients one week prior to transplantation. In contrast, many groups working
with tolerogenic dendritic cells (DCs) advocate post-transplant administration of recipient-derived cells. A third
alternative, using myeloid-derived suppressor cells, presumably demands that cells are given around the time of
transplantation, so that they can infiltrate the graft to create a suppressive environment. On present evidence, it is
not possible to say which cell type and treatment strategy might be clinically superior. This review seeks to position
our basic scientific and early-stage clinical studies of human regulatory macrophages within the broader context of
myeloid suppressor cell therapy in transplantation.
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The existence of anti-inflammatory T cell-suppressive
cells of the myeloid lineage has long been recognised
and the ability of such cells to induce tolerance to auto-
and allo-antigens after adoptive transfer has been stud-
ied extensively. Although often mooted, progress to-
wards clinical applications of myeloid suppressor cell
therapy was limited until recently, when several inde-
pendent groups began trials in transplantation [1-3],
rheumatoid arthritis [4] and diabetes [5]. Results from
these early-phase clinical studies have been promising,
at least in terms of demonstrating the feasibility and risk
profile of such approaches, but evidence of efficacy in
patients is still lacking. In this regard, the inception of
The ONE Study, a clinical trial of cell therapy as an ad-
junct immunosuppressive treatment in renal transplant-
ation, is a critical step forward [6].* Correspondence: paloma.riquelme@ukr.de
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medium, provided the original work is properCurrently, the concept of promoting immunological
regulation in transplant recipients by treating with mye-
loid suppressor cells of various types is being pursued by
a number of groups [7-9]. Depending upon their exact
nature and whether they are of donor, recipient or third-
party origin, different myeloid suppressor cells exert
their therapeutic effects through very different mecha-
nisms [10]. In turn, the immunological actions of par-
ticular myeloid suppressor cells determine how those
cells might be optimally delivered to patients, especially
with respect to timing and route of administration, and
immunosuppressive co-treatments. This review exam-
ines three radically alternative approaches to myeloid
suppressor cell therapy in transplantation, each with its
own clinical and immunological merits.
Broadly speaking, myeloid suppressor cells are charac-
terised either by an arrested state of immaturity, when
they are known as myeloid-derived suppressor cells
(MDSCs) or tolerogenic DCs, or by a more mature
phenotype, reflecting the ability of myeloid antigen-
presenting cells to switch into a suppressive mode underarticle distributed under the terms of the Creative Commons Attribution
by/2.0), which permits unrestricted use, distribution, and reproduction in any
ly cited.
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treatments prevent DC maturation in vitro, including
generation in the presence of IL-10 (DC-10) [11] or
rapamycin (Rapa-DC) [12], culture in low concentra-
tions of GM-CSF (Tol-DC)[13] or exposure to dexa-
methasone and vitamin D [4]. Paradoxically, various
pro-inflammatory factors can also drive macrophages
and DCs to a suppressive state, including IFN-γ, prosta-
glandin E2 (PGE2) and repetitive Toll-like Receptor
(TLR) stimulation. As we describe below, the regulatory
macrophage (M reg) is an important example of an
activation-induced myeloid suppressor cell.
It is not known whether the distinction between mye-
loid suppressor cells in a state of arrested immaturity
and those in an activation-induced suppressor state is
biologically meaningful. Certainly, many of the same
molecular mechanisms account for the suppressive ac-
tivities of both immature and activation-induced myeloid
suppressor cells (Table 1). It is also unclear whether the
various types of tolerogenic DCs and MDSCs described
in the literature represent unique cell subtypes, or
whether they are functionally interchangeable cells with
only superficial phenotypic differences. A workshop re-
cently convened by The ONE Study consortium in
Regensburg, Germany, should provide some insight into
these unresolved issues (see accompanying editorial [6]).Low GM-CSF
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Human regulatory macrophages
Efforts in our laboratory to develop a cell-based medi-
cinal product for use in promoting transplant tolerance
in renal transplant patients have focussed on M regs.
The human M reg reflects a unique state of macrophage
differentiation, distinguished from macrophages in other
activation states by its particular mode of derivation,
robust phenotype and potent T cell suppressor function.
These cells arise from CD14+ peripheral blood mono-
cytes during a seven-day culture period during which
the cells are exposed to M-CSF, 10% human serum and
a final 24-hour pulse of IFN-γ [14]. M regs derived in
this manner adopt a characteristic morphology and are
homogeneously CD14-/low HLA-DR+ CD80-/low CD86+
CD16- CD64+ TLR2- TLR4- and CD163-/low. M regs do
not stimulate allogeneic T cell proliferation in vitro
and, when co-cultured with polyclonally stimulated T
cells, are potently suppressive of proliferation. The
suppressive capacity of M regs has been attributed to
IFN-γ-induced indoleamine 2,3-dioxygenase (IDO)
activity, as well as contact-dependent deletion of acti-
vated T cells [3]. Critically, human M regs are rela-
tively resistant to maturation upon stimulation with
lipopolysaccharide (LPS), possibly as a consequence
of TLR down-regulation.TolDC
M
Tol DC
MSC-educated M
M reg
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ssor macrophages and DCs can be generated from monocytes using
o mature, activating DCs can be blocked by various substances,
ndered tolerogenic by culture in low-dose GM-CSF or by addition of
SC) can induce a suppressor phenotype in co-cultured macrophages.
onocytes/macrophages to tumour-secreted factors, most notably PGE2.
Table 1 Main characteristics of different myeloid suppressor APCs
Human phenotype Function Mechanism Trafficking Ref.
M reg CD14-/low, CD16-, CD80-/low,
CD40-/low, HLA-DR+, TLR2-,
CD83-, CD163-/low
T cell elimination, suppression
of T cell proliferation
IDO Lung, blood, liver, spleen [3,14-16]
Tol-DC HLA-DR+, low costimulation,
CD14+, CD11b+, resistant
to maturation
Allo-Ag capture and presentation,
suppression of T cell proliferation
HO-1, EBl3, iNOS Spleen [8,17-20]
DC-10 CD14+, CD16+, CD83+, CD1a-,
ILT4+, HLA-G+, IL-12-
Induction T cell anergy,
Tr-1 cell induction
IL-10, ILT-4-HLA-G
interactions
Blood and secondary
lymphoid organs
[21]
Rapa-DC HLA-DR+, low costimulation,
resistant to maturation, IL-12+
T cell hyporesponsiveness and
apoptosis, T reg induction
Low costimulation LN, spleen [22-26]
MDSC HLA-DR-/low, CD11b++,
CD14+, CD33+, CD34+
Suppression of T cell proliferation,
cytokine production, apoptosis
in T cells
iNOS, Arg-1, ROS, PGE2, HO-1,
TGF-β, cys depletion
Blood, graft, spleen, LN [27-32]
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tral venous infusion, allogeneic M regs labelled with
111Indium-oxine were administered to a single patient,
MM, whose case is described below [3]. Subsequently,
the anatomical distribution of the M regs was tracked
over 30 hours in serial whole-body Single Photon Emis-
sion Computed Tomography (SPECT) studies. Initially,
M regs were only detected in the lungs, but within
2.5 hours were found circulating in blood. By 30 hours
post-infusion, most M regs had emigrated from the
lungs to the spleen, liver and haematopoietically-active
bone marrow. M regs did not accumulate in lymph
nodes. We can be confident that the majority of infused
M regs survived for the duration of the follow-up, be-
cause tracer was not observed in the urinary tract or
blood.
Mouse regulatory macrophages
Mouse CD11b+ Ly6C+ bone marrow monocytes cultured
under conditions analogous to those used in the gener-
ation of human M regs give rise to a population of sup-
pressive macrophages which are highly similar to human
M regs in morphology, cell-surface phenotype and
in vitro function [16]. Mouse M regs express a selection
of typical macrophage markers, including CD11b,
CD11c, CD68, F4/80 and CD14, and exhibit a partially-
matured phenotype with intermediate levels of MHC
Class II and CD80, and no expression of CD40 or CD86.
Mouse M regs express sialoadhesin (CD169), macro-
phage scavenger receptor (CD204) and Dectin-1, but
lack other markers of notable tissue macrophage subsets,
such as Dectin-2, MARCO, CD4, CD206 and CD209.
M regs do not express Ly6C or Ly6G, which together
constitute the Gr-1 antigen that is expressed by all
mouse MDSCs. CD11c is homogenously expressed by
mouse M regs, but they do not express other DC subset-
defining markers, including 33D1, OX40L (CD252),
CD103, CD205 and CD207. Importantly, like human M
regs, mouse M regs do not express TLR2 or TLR4.Given its mode of derivation, morphology and cell-
surface phenotype, it seems most appropriate to classify
the M reg as a macrophage; however, mouse M regs do
not express markers typical of either M1-polarised
macrophages (eg. TNF-α, IL-6 and IL-12b) or M2-
polarised macrophages (eg. CD206, Ym1 or Fizz1). To
better understand the phenotypic relationship between
mouse M regs and previously-described macrophage po-
larisation states, we performed whole-genome gene ex-
pression studies to compare M regs to monocytes,
monocyte-derived DCs, resting macrophages, IFN-γ-
stimulated macrophages and M1-, M2a-, M2b- and M2c-
polarised macrophages: These experiments showed that
mouse M regs represent a novel and unique state of
macrophage activation. Mouse M regs inhibit T cell
responses in vitro by several mechanisms. Mitogen-
stimulated T cell proliferation is non-specifically inhibited
in co-cultures with M regs through the action of inducible
nitric oxide synthase (iNOS). M regs delete co-cultured
allogeneic T cells (but not isogeneic T cells) through an un-
known mechanism that ultimately leads to phagocytosis of
the T cells. Any T cells which survive direct co-culture with
M regs are impaired in their ability to secrete IL-2 and
IFN-γ upon specific and non-specific restimulation [16].
Preclinical experiments using a heterotopic mouse heart
transplant model demonstrate the potential of mouse M
regs to prolong allograft survival [16]. A single intravenous
administration of 5×106 donor-strain M regs at 8 days
prior to transplantation significantly prolongs allograft sur-
vival in unconditioned, non-immunosuppressed recipients
using both the stringent C3H-to-BALB/c (32.6±4.5
vs. 8.7±0.2 days) and B6-to-BALB/c (31.1± 12 vs
9.7±0.4 days) strain combinations. This graft-protective
effect is specific to donor cells, as recipient cells do not
prolong graft survival compared to untreated controls and
third party-derived M regs provide only a marginal benefit
(11.0±0.6 days). Improved graft survival is observed irre-
spective of whether M regs are administered 8 or 35 days
prior to transplantation. Co-treatment with M regs and
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enhances the graft-protective effect of M regs
(64.1±8.6 days) compared to treatment with M regs alone
or rapamycin alone, and some recipients co-treated with
M regs and rapamycin accept their allografts indefinitely.
The mechanism of M reg-mediated allograft protection is
iNOS-dependent because M regs derived from Nos2-
deficient mice only marginally prolong graft survival
(12.0±1.8 days). Very importantly, the iNOS-dependence
of M reg treatment in vivo proves that the graft-protective
effect of M regs is not simply due to alloantigen exposure,
but must be mediated by living, metabolically-competent
cells.Donor
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Figure 2 Proposed mode of M reg action. (1) When administered prior
present donor antigen through the direct pathway to alloreactive T cells an
cells. Human M regs have been shown to delete activated T cells through
through IDO; however, other suppressor mechanisms may also contribute
(2) It is likely that M regs serve as a source of donor alloantigen, which is c
cells via the indirect and semi-direct pathways of alloantigen recognition. I
antigen-specific T regs may be induced. (3) Through these mechanisms, th
reactive T cells. (4) After transplantation, recipient T regs could induce toler
DCs could then suppress activation of T cells. (6) In consequence, an immu
established.Several mutually redundant mechanisms might be
invoked to explain the effects of M regs in vivo and, in
our opinion, more than one mechanism is likely to be in
operation (Figure 2). It is well-known that pre-transplant
exposure to donor alloantigen promotes allograft accept-
ance [33] and that delivery of alloantigen as apototic cell
debris enhances this effect [34,35]. Both CD8α+ DCs
[36] and F4/80+ PD-L1+ IL-10-producing macrophages
[37] of the splenic marginal zone appear to be important
for the tolerogenic effects of complement-opsonised
apoptotic antigens [38]. After intravenous injection into
mice, isogeneic and allogeneic mouse M regs are initially
trapped in the pulmonary vasculature, then rapidlySecondary lymphoid tissue
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to transplantation, donor M regs migrate to spleen, where they
d either delete or anergise them, or induce expansion of regulatory T
a contact-dependent mechanism and to suppress T cell proliferation
to M reg function, such as IL-10 and TGF-β secretion, or iNOS activity.
aptured and presented by immature recipient DCs to alloreactive T
n consequence, responding T cells may be deleted or anergised, and
e recipient T cell pool is enriched for T regs and depleted of donor-
ogenic DCs in secondary lymphoid organs. (5) Recipient tolerogenic
nological environment conducive to allograft acceptance is
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liver and spleen, but not to lymph nodes [16]. Isogeneic
and allogeneic M regs are relatively short-lived after
transfer into immunocompetent mice, both being detect-
able at 2 weeks post-infusion, but not 4 weeks. These
experiments suggest that M regs have an inherently li-
mited lifespan after transfer; therefore, M regs probably
serve as a source of apoptotic donor alloantigen-
expressing material. Such a mechanism operates in
tolerance induction protocols using donor-specific trans-
fusion (DST) and αCD154 treatment, in which indirect
presentation of donor alloantigen results in a predomin-
antly deletional tolerance [39]. And yet, the graft-
protective effect of donor alloantigen exposure in the
absence of costimulatory blockade or lymphodepletive
conditioning [40] is rarely as profound as that achieved
with M reg treatment, even in less stringent transplant
models. Moreover, it is difficult to reconcile the require-
ment for iNOS expression by transferred M regs with
the suggestion that M regs act merely as a passive source
of alloantigen. It is possible that mouse M regs directly
suppress T cell responses in vivo through iNOS activity,
as they do in vitro, but the critical action of iNOS might
equally be mediated by recipient APCs [41,42]. Accor-
dingly, one important fate of M regs might be to migrate
into tissues, induce a suppressive condition in recipient
APCs, before dying in a suitably self-conditioned
environment.
MDSCs and tolerogenic DCs
Naturally-occuring myeloid suppressor cells fall into
three ‘classes’: those present in non-inflamed tissues;
those arising in inflamed tissues; and dedicated myeloid
suppressor cell populations which are recruited to both
inflamed and non-inflamed tissues. The ‘default’ condi-
tion of immature DCs and macrophages in non-
inflamed tissues is suppressive; such cells play crucial
roles in the maintenance of tissue homeostasis and self-
tolerance, as well as resisting the otherwise perpetual ac-
tivation of inflammatory responses [43]. Suppressive
macrophages and DCs can also arise in inflamed tissues
through conversion from activated, mature APCs; such
cells limit the extent of inflammatory responses and pro-
mote tissue-reparative processes and the re-establish-
ment of tissue homeostasis [44]. Committed myeloid
suppressor cell populations, collectively known as
MDSCs, are present in blood and can infiltrate both
inflamed and non-inflamed tissues, including allografts
and tumours [45]. These three general classes of
naturally-occurring myeloid suppressor cell are reflected
by the types of myeloid suppressor cell that can be gen-
erated in vitro.
Immature macrophages and DCs are normal stromal
components of almost all peripheral tissues, where theyserve many vital functions, including the removal of
dead cells, microbial products and other tissue debris by
phagocytosis, and the maintenance of a non-inflammatory
environment through secretion of suppressive mediators.
The immature state of tissue-resident macrophages and
DCs is stabilised by anti-inflammatory factors present in
non-inflamed tissues, such as IL-10 and glucocorticoid.
Colonic macrophages exemplify the role of immature,
tissue-resident APCs in preventing aberrant inflammatory
responses; these cells respond to IL-10 by secreting IL-10,
which suppresses the continual inflammation that would
otherwise be caused by gut commensals and their pro-
ducts [46]. Besides their local effects in tissues, imma-
ture DCs deliver self-antigens to secondary lymphoid
organs, where they are presented to T cells in a poor co-
stimulatory context to propagate self-tolerance. Many
in vitro-derived tolerogenic DCs fit this description of a
phagocytic, maturation-resistant cell with the ability to
present antigen in the absence of strong co-stimulation,
including DC-10, Rapa-DC and Tol-DC [10]. A wide
range of unrelated stimuli drive DCs to suppressive
states, so there is no unique phenotype or mechanism
of action associated with tolerogenic DC populations
(Table 1). Generically, human tolerogenic DCs express
cell-surface markers typical of immature monocyte-
derived DCs, but there are markers of specific subtypes:
Tol-DC are CD11c+ CD11b+ EBI3+ cells; DC-10 express
high levels of HLA-G, ILT4 and secrete IL-10; Rapa-DC
lack expression of CD80 and CD86, express only low-
levels of HLA-DR, but secrete significant amounts of
IL-12. These three tolerogenic DC subtypes exert their
suppressive effects through alternative mechanisms,
specifically: Tol-DC inhibit T cell responses through
haemoxygenase (HO)-1 activity and T reg expansion
[17]; DC-10 suppress T cell proliferation and induce
antigen-specific Tr-1 cells through IL-10 production
[21]; Rapa-DC induce effector T cell anergy and pro-
mote FoxP3+ T reg generation by presenting antigen in
the absence of costimulation. Tolerogenic DC popula-
tions also differ in their migratory capacity in vivo. Stud-
ies in animals have shown that Rapa-DCs traffic to
lymph nodes [25,26], but that Tol-DCs migrate prefer-
entially to spleen [8,20].
In response to tissue injury or detection of pathogens,
tissue-resident macrophages and DCs initiate a localised
inflammatory response, involving the recruitment of
other immunological effector cells, resulting in second-
ary tissue damage. However, this destructive behaviour is
usually only transient, because activated macrophages
and DCs switch to an anti-inflammatory and tissue-
reparative mode [44]. The ability of macrophages to both
exacerbate and attenuate inflammatory reactions is
neatly illustrated by their contribution to ischaemia-
reperfusion injury and its resolution: Experimental
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reperfusion injury reduces the number of infiltrating leu-
cocytes and helps to preserve short-term kidney function
[47]; however, the cost of preventing early macrophage-
mediated injury is a worse tissue repair response and
impaired long-term function [48]. We regard human M
regs, which are activated during cell culture by adhe-
rence to plastic, serum components and IFN-γ, as
belonging to the class of activation-induced (or ‘deacti-
vated’) myeloid suppressor cells.
MDSCs represent a third class of myeloid suppressor
cell, which is characterised by the expression of markers
associated with myeloid progenitors and commitment to a
suppressor phenotype prior to entering tissues from blood.
Although MDSC populations in mice and humans are
highly heterogenous, any standard definition of mouse
MDSCs includes expression of CD11b and Gr-1, whereas
human MDSCs universally express CD11b, CD33, CD34
and VEGFR1 [45]. It is well-established that MDSCs exert
a local immunosuppressive effect within solid tumours
[49,50] and it appears that they have a similar function in
transplanted organs, because induction of tolerance to kid-
ney, skin and cardiac allografts is associated with infiltra-
tion of grafts by MDSCs [28,51].
Alternative clinical approaches
In principle, myeloid suppressor cells could favour
allograft acceptance in several ways. Firstly, myeloid sup-
pressor cells could exert transient, general immunosup-
pressive effects by secreting anti-inflammatory mediators
or releasing of apoptotic debris. Secondly, myeloid sup-
pressor cells could suppress inflammation and promote
tissue repair processes within allografts during the im-
mediate postoperative period. Thirdly, myeloid suppres-
sor cells could anergize or delete recipient effector
T cells, or induce alloantigen-specific regulatory T cells.
Intuitively, the relative contribution of these allograft-
protective mechanisms to transplant survival will
depend on the route and timing of therapeutic cell
administration, and the type of myeloid suppressor cell
being used.
Pre-transplant versus post-transplant cell administration
Arguably, the state of the immune system prior to trans-
plantation is more conducive to the establishment of tol-
erance than afterwards. Under steady-state, physiological
conditions, immature DCs capture and present innocu-
ous antigens leading to the anergy or deletion of
antigen-reactive effector T cells and the expansion of
specific T regs [9]. Organ transplantation disrupts this
homeostatic condition by causing massive inflammation
and the abrupt activation of vast numbers of alloreactive
recipient T cells. Hence, the rationale for using myeloidsuppressor cells prior to transplantation is that enrich-
ment of alloantigen-specific T regs and deletion of ef-
fector T cells should be easier in an immunological
environment naturally predisposed to the maintenance
of tolerance. In addition, conventional immunosuppres-
sive therapy might antagonise the regulatory action of
myeloid suppressor cells given after transplantation.
Whilst exploiting the pro-tolerogenic condition of the
pre-transplant immune system seems a sensible thera-
peutic strategy, a few arguments have been levelled
against this approach. Firstly, and most importantly, in
order to induce antigen-specific immunological regula-
tion prior to transplantation, it is necessary to deliber-
ately expose the recipient to donor alloantigen, which
carries an attendant risk of allo-sensitisation. Secondly,
patients with end-stage organ failure awaiting trans-
plantation may not be in a immunologically quiescent
state, either because of their underlying disease or con-
current subclinical infections. Thirdly, pre-treatment
with donor-derived myeloid suppressor cells is not
possible in the case of transplantation from deceased
donors.
Myeloid suppressor cells of donor versus recipient origin
From an immunological standpoint, the principal reason
for using myeloid suppressor cells of donor origin is to
expose the recipient to intact donor alloantigen via the
direct and semi-direct pathways. Alloantigen released by
donor-derived cells could also be captured and pre-
sented in a pro-tolerogenic context by immature recipi-
ent DCs via the indirect pathway [52]. Consequently,
donor-derived myeloid suppressor cells find their main
application in pre-transplant conditioning therapies
[3,53]. Donor-derived cells have the advantage that they
can be reliably obtained from healthy, living donors.
Recipient-derived myeloid suppressor cells are less likely
to be eliminated by recipient T cells and NK cells, so
have a greater capacity to migrate and engraft, and are
less likely to sensitise the recipient against donor alloan-
tigen. Production of recipient-derived myeloid suppres-
sor cells prior to deceased-donor transplantation is
feasible; however, since recipient-derived myeloid sup-
pressor cells must capture and present graft-derived
alloantigen in the indirect pathway, postoperative
administration is the generally favoured approach of
groups working with recipient-derived cells. Recipient-
derived myeloid suppressor cells can be loaded with
donor-alloantigen prior to infusion and this approach
has proven to be a very effective therapy in animal mod-
els. Notably, antigen-pulsed tolerogenic DC were found
to induce transplantation tolerance by expanding T regs
which recognised alloantigen in the indirect pathway
[25]. It has also been suggested that using third-party
myeloid suppressor cells could eliminate some of the
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though it is difficult to envisage how third-party cells
could induce allo-specific regulation, especially consider-
ing that the use of third-party tolerogenic DCs shows
little or no effect in many animal models [20,25,54].
Route of administration
Selecting a route of administration for a tolerogenic cell
therapy involves a trade-off between the most efficient
means of delivering cells to their site of action and issues
of clinical practicality and safety. Most animal experi-
ments with myeloid suppressor cells have evaluated their
therapeutic potential after intravenous administration
[16,20,25], although some groups have investigated sub-
cutaneous [55] and intramuscular injection [26]. The
intravenous route seems quite suitable for M regs, since
they normally traffic to liver, spleen and bone marrow.
Tol-DCs and Rapa-DCs prolong allograft survival after
intravenous injection; however, because recipient-
derived tolerogenic DCs must capture graft antigens and
suppress T cell activation in graft-draining lymph nodes,
direct application of cells into lymph nodes may prove a
superior route of administration. Since MDSCs exert im-
portant immunosuppressive actions within allografts, the
possibility of injecting them directly into the arterial
supply of the transplanted organ deserves further
investigation.
Clinical applications of M reg therapy
As we have seen, when applying myeloid suppressor cell
therapy in solid organ transplantation, the choice of
myeloid suppressor cell type, whether it is given pre- or
post-transplantation, whether it is of donor or recipient
origin, and its route of administration are interdepend-
ent considerations (Table 2).
On the present evidence, we cannot say which cell
type or clinical approach represents an optimal therapy;
however, based on our preclinical animal studies and the
outcomes of the TAIC-I and TAIC-II clinical trials, our
research group favours the preoperative administration
of donor-derived M regs. A handful of clinical trials have
been conducted (or are presently underway) using tol-
erogenic DCs in the treatment of Type I diabetes [5] and
rheumatoid arthritis [4]; however, these cells have not
yet been applied in solid organ transplantation. As weTable 2 Clinical translation of myeloid suppressor cell therap
Origin Time
M reg Donor Pre- M
Tol-DC Recipient Peri-/post-
DC-10 Recipient/Donor DC10+ recipient Tr-1 Peri-/post-
Rapa-DC Donor-pulsed recipient Pre-Post
MDSC Recipient Peri-/Post-describe below, M reg-containing cell preparations have
now been trialled in a total of 21 renal transplant recipi-
ents (Table 3).
The TAIC-I clinical trial
The TAIC-I trial was a single-centre, open-label, single-
arm study with the objective of obtaining information
on the safety and tolerability of administering M reg-
containing cell preparations to renal transplant recipi-
ents (http://www.clinicaltrials.gov, NCT00223093) [1]. A
total of 12 patients receiving their first transplant from a
deceased donor were enrolled in the study. Initially
immunosuppression comprised tacrolimus, sirolimus
and corticosteroids. From week 4 posttransplantation,
patients were aggressively weaned from immunosup-
pressive therapy with the intention of achieving tacroli-
mus monotherapy (8–10 ng/ml trough level) by week 12
and further reduction to ≤4 ng/ml within 24 weeks.
Patients were treated with 0.9–5.0 × 108 donor-derived
cells by central venous infusion at 5 days after trans-
plantation (Figure 3). No acute complications or later
adverse reactions relating to the cell infusion were
observed. Thus, the TAIC-I trial demonstrated the
clinical feasibility of producing and administering M
reg-containing cell preparations to kidney transplant
recipients.
The TAIC-II clinical trial
The TAIC-II study was a phase I/II clinical trial (http://
www.clinicaltrials.gov, NCT00223067) designed to assess
the safety and efficacy of administering donor-derived M
reg-containing cell preparations to recipients of living-
donor renal transplants [2]. Five days prior to surgery,
five living-related kidney transplant recipients were trea-
ted with 1.4-5.9 × 108 cells (Figure 4). No clinical compli-
cations of the cell infusion were observed. All patients
received induction therapy with anti-thymocyte globulin
(ATG) on days 0, 1 and 2. From the time of transplant-
ation onwards, patients received a dual immunosuppres-
sive regime comprising conventional steroid treatment
and tacrolimus therapy, aiming for trough levels of
8–12 ng/ml. Steroids were weaned by week 8 post-
transplantation and tacrolimus was reduced to 5–8 ng/ml
over several weeks. Four patients were successfully mini-
mised to low-dose tacrolimus monotherapy. No rejectiony in solid organ transplantation
Pre-clinical Clinical Ref.
ouse, pig, dog TAIC- I, TAIC-II, The ONE Study [1-3,6,16,56-58]
Rat, NHP The ONE Study [6,18,20,53,54]
Rat - [59]
Mouse - [25]
Mouse - [60]
Table 3 Clinical studies with regulatory macrophages
Study n Source Time Total cell number Cells/kg body weight Ref.
KW 1 Donor spleen +5 1.1 × 106 [56]
TAIC-I 12 Donor spleen +5 0.9-5 × 108 1-7.5 × 106 [1]
FR 1 Donor blood −17 4.8 × 109 6.9 × 107 [57]
TAIC-II 5 Donor blood −5 1.4-5.9 × 109 1.7-10.4 × 107 [2]
M reg: MM, CA 2 Donor blood −6/7 4.3-7.5 × 108 7-8 × 106 [3]
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http://www.transplantationresearch.com/content/1/1/17occurred in two of five patients. Following the reduction
of tacrolimus treatment to <2 ng/ml for 6 weeks, one pa-
tient underwent a rejection episode at 36 weeks. The two
remaining patients experienced acute rejection episodes
only after complete cessation of immunosuppression for 2
and 34 weeks. All patients in TAIC-II were monitored for
indices of graft acceptance and rejection through the
RISET network. None of the patients developed anti-
donor HLA antibodies as a consequence of M reg admin-
istration and no accelerated graft loss occurred. Anti-
donor T cell reactivity was serially assayed by MLR and
was found to be consistently reduced.Patients MM and CA
Since the TAIC-I and TAIC-II clinical trials, we have
arrived at a detailed understanding of the derivation,
phenotype and T cell-suppressive functions of in vitro-
derived human regulatory macrophages. This knowledge
has inspired methodological advances in regulatory
macrophage manufacture, leading to a far purer and
more homogeneous cell product, which has now been
applied to two further living-donor renal transplant reci-
pients with encouraging results [3].
The first of these patients, MM, a 23 year-old female
with renal failure owing to IgA nephropathy, received a
living-donor kidney transplant from her 58 year-old
mother. Mother and daughter had only single HLA-B
and- DR mismatches (Figure 5). Six days prior to trans-
plantation, patient MM received 8.0 × 106 donor-derived
M regs/kg by slow central venous infusion under cover
of 2 mg/kg/d azathioprine. Conventional treatment with
steroids and tacrolimus was started at the time of trans-
plantation. Azathioprine was stopped at 8 weeks post-
transplant and steroids were weaned by 14 weeks.
Thereafter, MM was maintained on tacrolimus mono-
therapy with trough levels of less than 6 ng/ml. Protocol
biopsies at 8 and 24 weeks showed no signs of rejection.
At 3 years, MM was in a stable clinical condition, receiv-
ing tacrolimus 2 mg BD with trough levels of 4–5 ng/ml
as her sole maintenance immunosuppression.
The second patient, CA, a 47 year-old man, received a
fully-mismatched kidney from a 40 year-old living, unre-
lated male donor. CA was treated with 7.1 × 106 donor-
derived M regs/kg seven days prior to transplantationunder cover of 2 mg/kg/d azathioprine. Treatment with
tacrolimus and steroids began the time of transplan-
tation. Protocol biopsies at 8, 24 and 52 weeks showed
no signs of rejection. At 3 years post-transplantation,
CA had stable renal function and was being maintained
with sustained-release tacrolimus 5 mg OD with a
trough tacrolimus level of 2.7 ng/ml.
Minimising the maintenance immunosuppression of
renal transplant recipients to tacrolimus monotherapy is
not recommended by the Kidney Disease Improving
Global Outcomes (KDIGO) guidelines, which advise the
combination of a calcineurin inhibitor and an antiproli-
ferative agent, with or without corticosteroids [61].
Nevertheless, in practice, patients receiving tacrolimus
monotherapy are not uncommon and use of Alemtuzumab
induction as a means of establishing patients on mainte-
nance tacrolimus monotherapy has stimulated much
recent interest. So, should we be surprised by the clinical
outcomes of MM and CA? Although, we must be cautious
in our interpretation of these two case studies, there are
intriguing aspects of MM and CA’s histories that deserve
particular mention: Both patients were minimised to low-
dose tacrolimus monotherapy; this reduction in tacrolimus
dosing was made relatively early after transplantation;
neither MM nor CA received conventional induction
therapy; and, both MM and CA developed a peripheral
blood biomarker profile converging upon the IOT-
RISET signature of tolerance [62].
What constitutes low-dose tacrolimus therapy? Defini-
tions of low-dose and standard-dose tacrolimus treat-
ment are largely a matter of convention. The Symphony
Study, which assessed whether a mycophenolate mofetil
(MMF)-based regimen allows minimisation of adjunct
immunosuppression, incorporated a low-dose tacrolimus
arm in which 75% of patients had trough tacrolimus
levels of 4.3-10.0 ng/mL [63]. By this standard, MM and
CA were treated with very low-dose tacrolimus, since
both patients registered drug levels in the lowest 12.5
percentile of this range [64]. Unlike subjects in the Sym-
phony Study, patients MM and CA were not given
Dacluzimab induction or maintenance MMF therapy.
Viewed in this context, the fact that both MM and CA
remain rejection-free and with stable graft function at
>4 years post-transplantation is an encouraging
outcome.
Immunosuppression with Tacrolimus, Sirolimus and corticosteroids
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Complete withdrawal of all immunosuppressive therapy
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ge
n
d
Excluded
Excluded
WW
FK
Figure 3 Overview of the TAIC-I trial. Patients enrolled in the TAIC-I Study each received a kidney transplant from a deceased donor. The
mean age of the patients was 46.3 years and 9/12 patients were male. The median HLA-A,-B and –DR mismatch was 5/6. Initially, patients were
treated with a combination of tacrolimus (trough levels of 10–15 ng/ml), sirolimus (trough levels of 4–8 ng/ml) and corticosteroids. Cells were
infused on day 5 post-transplant. Steroids were tapered in weeks 5 and 6. Sirolimus was withdrawn in weeks 7 and 8. If graft function remained
stable, tacrolimus treatment was first minimised to trough tacrolimus levels of 8–10 ng/ml by week 12 and then to levels of 5–8 ng/ml by week
24. Further reductions in tacrolimus therapy were undertaken in patients with stable graft function and no histological evidence of rejection.
Figure reproduced with permission from Hutchinson, JA. et al. Transplant International (2008) 21:728–741.
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http://www.transplantationresearch.com/content/1/1/17Is low-dose tacrolimus monotherapy difficult to achieve
in renal transplant recipients? Shapiro’s 2003 study remains
a benchmark trial of minimised tacrolimus monotherapy
in renal transplant recipients [65]. 150 patients were trea-
ted with 5 mg/kg ATG and bolus prednisone as an induc-
tion therapy, and were subsequently maintained tacrolimus
monotherapy, which was minimised in a step-wise fashionover many months (Figure 6). Under this regimen, 37% of
patients underwent acute rejection prior to minimisation
of tacrolimus dosing. 113 patients were then selected to
undergo tacrolimus weaning: These patients were
followed-up for a mean of 11±5.4 months, during which
time 23% of patients underwent acute rejection. Other
studies with the aim of establishing renal transplant patients
0 10 20 30 40 50 60 70 80
Time post-transplantation (weeks)
Complete withdrawal of all immunosuppressive therapy
Tacrolimus monotherapy, trough serum levels: <4 ng/ml
Tacrolimus monotherapy, trough serum levels: 4 - 8 ng/ml
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Exit from trial with histologically confirmed rejection
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ge
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Follow-up
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Figure 4 Overview of the TAIC-II trial. Patients enrolled in the TAIC-II Study each received a kidney transplant from a living donor. The mean
age of the patients was 35.4 years and 4/5 patients were male. The median HLA-A,-B and –DR mismatch was 3/6. Cells were infused 5 days prior
to transplantation. All patients received ATG induction therapy on days 0, 1 and 2. Initial maintenance immunosuppression comprised
glucocorticoids and tacrolimus (8–12 ng/ml trough levels). Steroid therapy was withdrawn by week 10. Tacrolimus dosing was then adjusted into
a target range of 5 – 8 ng/ml trough levels. From week 24 onwards, further reductions were made in tacrolimus monotherapy, leading to
complete drug withdrawal in two patients.
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http://www.transplantationresearch.com/content/1/1/17on tacrolimus monotherapy after ATG induction achieved
similar outcomes [66]. More recently, Alemtuzumab induc-
tion with tacrolimus monotherapy has been used with some
success [67]. Margreiter et al. reported a 20% 1-year bi-
opsy-proven acute rejection rate in patients undergoing
Alemtuzumab induction, followed by tacrolimus monother-
apy with trough drug levels of 8–12 ng/ml for 6 months,
reduced to 5–8 ng/ml thereafter [68]. More impressively,
Chan and colleagues observed an 89.9% 2-year rejection-
free renal allograft survival rate using Alemtuzumab
and tacrolimus monotherapy with a target-range of 5–
8 ng/ml [69]. Clearly, tacrolimus monotherapy can be
achieved in renal transplant patients treated with a
powerful induction agent, such as Alemtuzumab; never-
theless, it is still surprising that patients MM and CA,
who were not treated with T cell-depleting monoclonal
antibodies, were able to tolerate an early, fairly abrupt
minimisation of immunosuppression.
A pattern of peripheral blood gene expression asso-
ciated with a drug-free, tolerant state in renaltransplant recipients has been defined by the IOT-
RISET consortium [62]. To assess the immunological
consequences of M reg therapy on patients MM and
CA, expression of the ten most discriminatory gene
markers of tolerance identified by the IOT-RISET
group was quantified in serial blood samples taken
from both patients [3]. Over the first year post-transplant,
the pattern of expression of these markers gradually
converged upon the IOT-RISET gene signature, sug-
gesting that MM and CA might have achieved a degree
of immunological regulation against their donors. To
put this result into context, we have to consider the
frequency of renal transplant recipients on CNI mono-
therapy whose gene expression profiles converge on
the IOT-RISET signature: Of the 30 patients on CNI
monotherapy included in the IOT-RISET cohort, all of
whom were 6 to 9 years post-transplantation, only 5
displayed such a gene expression profile. Because the
IOT-RISET study purposefully selected long-term, clin-
ically stable patients, it is likely that 16% is an over-
Azathioprine 2 mg/kg/day
Immunosuppression with Tacrolimus (8-12 ng/ml target trough level) and corticosteroids
Steroid weaning phase
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Figure 5 Overview of the treatment of patients MM and CA. Both patients received a living-donor kidney transplant. M regs were infused 6
(MM) or 7 (CA) days prior to transplantation under cover of 2 mg/kg/day azathioprine. Initial maintenance immunosuppression comprised
glucocorticoids and tacrolimus (>8 ng/ml trough levels). Steroid therapy was withdrawn by week 10. Tacrolimus dosing was then adjusted into a
target range of 4 – 8 ng/ml trough levels.
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http://www.transplantationresearch.com/content/1/1/17suppress T cell responses against alloantigen and to pro-
long allograft survival. This review has presented three
very different strategies for myeloid cell therapy in solid
organ transplantation. The particular cellular and mo-
lecular functions of different myeloid suppressor APCs
might make each cell type more suitable for different
clinical applications: Donor-derived M regs are to be
used pre-operatively to induce donor-specific regulation,
whereas recipient-derived suppressor cells and MDSCs
have to be used peri- or post-operatively. Translation of
myeloid suppressor APC therapy to the clinic is already
underway. Several patients have now been treated with
M regs in early-phase clinical trials and tolerogenic DCs
are currently being tested in rheumatoid arthritis and
diabetes studies. The ONE Study consortium is under-
taking a clinical trial which should allow a side-by-side
comparison of M regs and Tol-DC as adjunct immuno-
suppressive therapies in renal transplantation. The
results of this study are awaited with great excitement.
Abbreviations
Ag: Antigen; APC: Antigen presenting cell; CNI: Calcineurin inhibitor;
IL: Interleukin; M-CSF: Monocyte colony stimulating factor; GM-CSF: Granulocyte
monocyte colony stimulating factor; LN: lymph node; T reg: Regulatory T cell;
MLR: Mixed lymphocyte reaction; NHP: Non-human primate.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
PR wrote the manuscript with assistance from EKG and JAH. All authors read
and approved the final manuscript.
Acknowledgements
The authors wish to thank Mr. Ben James for proof-reading this article.
Received: 7 May 2012 Accepted: 18 September 2012
Published: 28 September 2012
References
1. Hutchinson JA, Riquelme P, Brem-Exner BG, Schulze M, Matthai M, Renders
L, Kunzendorf U, Geissler EK, Fandrich F: Transplant acceptance-inducing
cells as an immune-conditioning therapy in renal transplantation. Transpl
Int 2008, 21:728–741.
2. Hutchinson JA, Brem-Exner BG, Riquelme P, Roelen D, Schulze M, Ivens K,
Grabensee B, Witzke O, Philipp T, Renders L, et al: A cell-based approach to
the minimization of immunosuppression in renal transplantation. Transpl
Int 2008, 21:742–754.
3. Hutchinson JA, Riquelme P, Sawitzki B, Tomiuk S, Miqueu P, Zuhayra M,
Oberg HH, Pascher A, Lutzen U, Janssen U, et al: Cutting Edge:
immunological consequences and trafficking of human regulatory
macrophages administered to renal transplant recipients. J Immunol
2011, 187:2072–2078.
4. Harry RA, Anderson AE, Isaacs JD, Hilkens CM: Generation and
characterisation of therapeutic tolerogenic dendritic cells for rheumatoid
arthritis. Ann Rheum Dis 2010, 69:2042–2050.
5. Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M: Phase I (safety)
study of autologous tolerogenic dendritic cells in type 1 diabetic
patients. Diabetes Care 2011, 34:2026–2032.
6. Geissler EK: The ONE Study compares cell therapy products in organ
transplantation: introduction to a review series on suppressive
monocyte-derived cells. Transplantation Research 2012, 1:11 doi:10.1186/
2047-1440-1-11.7. Hutchinson JA, Riquelme P, Geissler EK: Human regulatory macrophages
as a cell-based medicinal product. Curr Opin Organ Transplant 2012,
17:48–54.
8. Beriou G, Moreau A, Cuturi MC: Tolerogenic dendritic cells: applications
for solid organ transplantation. Curr Opin Organ Transplant 2012, 17:42–47.
9. Thomson AW: Tolerogenic dendritic cells: all present and correct? Am J
Transplant 2010, 10:214–219.
10. Morelli AE, Thomson AW: Tolerogenic dendritic cells and the quest for
transplant tolerance. Nat Rev Immunol 2007, 7:610–621.
11. Amodio G: Human tolerogenic DC-10: perspectives for clinical
applications. Transplantation Research 2012, 1:14 doi:10.1186/2047-
1440-1-14
12. Macedo C: Immunoregulatory properties of rapamycin-conditioned
monocyte-derived dendritic cells and their role in transplantation.
Transplantation Research 2012, 1:16 doi:10.1186/2047-1440-1-16.
13. Moreau A: Cell therapy using tolerogenic dendritic cells in
transplantation. Transplantation Research 2012, 1:13 doi:10.1186/2047-
1440-1-13.
14. Hutchinson JA, Riquelme P, Geissler EK, Fandrich F: Human regulatory
macrophages. Methods Mol Biol 2011, 677:181–192.
15. Riquelme P, Govert F, Geissler EK, Fandrich F, Hutchinson JA: Human
transplant acceptance-inducing cells suppress mitogen-stimulated T cell
proliferation. Transpl Immunol 2009, 21:162–165.
16. Riquelme P, Tomiuk S, Kammler A, Fandrich F, Schlitt HJ: Geissler EK.
Hutchinson JA: IFN-gamma-induced iNOS Expression in Mouse
Regulatory Macrophages Prolongs Allograft Survival in Fully
Immunocompetent Recipients. Mol Ther; doi:10.1038/mt.2012.168.
17. Chauveau C, Remy S, Royer PJ, Hill M, Tanguy-Royer S, Hubert FX, Tesson L,
Brion R, Beriou G, Gregoire M, et al: Heme oxygenase-1 expression inhibits
dendritic cell maturation and proinflammatory function but conserves
IL-10 expression. Blood 2005, 106:1694–1702.
18. Moreau A, Hill M, Thebault P, Deschamps JY, Chiffoleau E, Chauveau C,
Moullier P, Anegon I, liot-Licht B, Cuturi MC: Tolerogenic dendritic cells
actively inhibit T cells through heme oxygenase-1 in rodents and in
nonhuman primates. FASEB J 2009, 23:3070–3077.
19. Hill M, Thebault P, Segovia M, Louvet C, Beriou G, Tilly G, Merieau E,
Anegon I, Chiffoleau E, Cuturi MC: Cell therapy with autologous
tolerogenic dendritic cells induces allograft tolerance through
interferon-gamma and epstein-barr virus-induced gene 3. Am J
Transplant 2011, 11:2036–2045.
20. Peche H, Trinite B, Martinet B, Cuturi MC: Prolongation of heart allograft
survival by immature dendritic cells generated from recipient type bone
marrow progenitors. Am J Transplant 2005, 5:255–267.
21. Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani CF,
Hauben E, Roncarolo MG: Differentiation of type 1T regulatory cells (Tr1)
by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway.
Blood 2010, 116:935–944.
22. Turnquist HR, Cardinal J, Macedo C, Rosborough BR, Sumpter TL, Geller DA,
Metes D, Thomson AW: mTOR and GSK-3 shape the CD4+ T-cell
stimulatory and differentiation capacity of myeloid DCs after exposure
to LPS. Blood 2010, 115:4758–4769.
23. Naranjo-Gomez M, Raich-Regue D, Onate C, Grau-Lopez L, Ramo-Tello C,
Pujol-Borrell R, Martinez-Caceres E, Borras FE: Comparative study of
clinical grade human tolerogenic dendritic cells. J Transl Med 2011, 9:89.
24. Turnquist HR, Fischer RT, Thomson AW: Pharmacological modification of
dendritic cells to promote their tolerogenicity in transplantation.
Methods Mol Biol 2010, 595:135–148.
25. Taner T, Hackstein H, Wang Z, Morelli AE, Thomson AW: Rapamycin-
treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell
regulation and prolong graft survival. Am J Transplant 2005, 5:228–236.
26. Reichardt W, Durr C, Von ED, Juttner E, Gerlach UV, Yamada M, Smith B,
Negrin RS, Zeiser R: Impact of mammalian target of rapamycin inhibition
on lymphoid homing and tolerogenic function of nanoparticle-labeled
dendritic cells following allogeneic hematopoietic cell transplantation.
J Immunol 2008, 181:4770–4779.
27. Greten TF, Manns MP, Korangy F: Myeloid derived suppressor cells in
human diseases. Int Immunopharmacol 2011, 11:802–807.
28. Dugast AS, Haudebourg T, Coulon F, Heslan M, Haspot F, Poirier N, de
Vuillefroy SR, Usal C, Smit H, Martinet B, et al: Myeloid-derived suppressor
cells accumulate in kidney allograft tolerance and specifically suppress
effector T cell expansion. J Immunol 2008, 180:7898–7906.
Riquelme et al. Transplantation Research 2012, 1:17 Page 13 of 14
http://www.transplantationresearch.com/content/1/1/1729. De Wilde V, Van RN, Hill M, Lebrun JF, Lemaitre P, Lhomme F, Kubjak C,
Vokaer B, Oldenhove G, Charbonnier LM, et al: Endotoxin-induced
myeloid-derived suppressor cells inhibit alloimmune responses via heme
oxygenase-1. Am J Transplant 2009, 9:2034–2047.
30. Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P: Positive
feedback between PGE2 and COX2 redirects the differentiation of
human dendritic cells toward stable myeloid-derived suppressor cells.
Blood 2011, 118:5498–5505.
31. Li Z, Pang Y, Gara SK, Achyut BR, Heger C, Goldsmith PK, Lonning S, Yang L:
Gr-1+CD11b+cells are responsible for tumor promoting effect of TGF-
beta in breast cancer progression. Int J Cancer 2012, 131:2584–2595.
32. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S:
Myeloid-derived suppressor cells inhibit T-cell activation by depleting
cystine and cysteine. Cancer Res 2010, 70:68–77.
33. Bushell A, Karim M, Kingsley CI, Wood KJ: Pretransplant blood transfusion
without additional immunotherapy generates CD25 +CD4+ regulatory T
cells: a potential explanation for the blood-transfusion effect.
Transplantation 2003, 76:449–455.
34. Morelli AE, Larregina AT: Apoptotic cell-based therapies against transplant
rejection: role of recipient’s dendritic cells. Apoptosis 2010, 15:1083–1097.
35. Steinman RM, Turley S, Mellman I, Inaba K: The induction of tolerance by
dendritic cells that have captured apoptotic cells. J Exp Med 2000,
191:411–416.
36. Qiu CH, Miyake Y, Kaise H, Kitamura H, Ohara O, Tanaka M: Novel
subset of CD8{alpha} + dendritic cells localized in the marginal zone
is responsible for tolerance to cell-associated antigens. J Immunol
2009, 182:4127–4136.
37. Getts DR, Turley DM, Smith CE, Harp CT, McCarthy D, Feeney EM, Getts MT,
Martin AJ, Luo X, Terry RL, et al: Tolerance induced by apoptotic antigen-
coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic
macrophages and maintained by T regulatory cells. J Immunol 2011,
187:2405–2417.
38. Morelli AE, Larregina AT, Shufesky WJ, Zahorchak AF, Logar AJ, Papworth GD,
Wang Z, Watkins SC, Falo LD Jr, Thomson AW: Internalization of circulating
apoptotic cells by splenic marginal zone dendritic cells: dependence on
complement receptors and effect on cytokine production. Blood 2003,
101:611–620.
39. Quezada SA, Fuller B, Jarvinen LZ, Gonzalez M, Blazar BR, Rudensky AY,
Strom TB, Noelle RJ: Mechanisms of donor-specific transfusion tolerance:
preemptive induction of clonal T-cell exhaustion via indirect
presentation. Blood 2003, 102:1920–1926.
40. Pearson TC, Madsen JC, Larsen CP, Morris PJ, Wood KJ: Induction of
transplantation tolerance in adults using donor antigen and anti-CD4
monoclonal antibody. Transplantation 1992, 54:475–483.
41. Ren G, Su J, Zhao X, Zhang L, Zhang J, Roberts AI, Zhang H, Das G,
Shi Y: Apoptotic cells induce immunosuppression through dendritic
cells: critical roles of IFN-gamma and nitric oxide. J Immunol 2008,
181:3277–3284.
42. Lu L, Bonham CA, Chambers FG, Watkins SC, Hoffman RA, Simmons RL,
Thomson AW: Induction of nitric oxide synthase in mouse dendritic cells
by IFN-gamma, endotoxin, and interaction with allogeneic T cells: nitric
oxide production is associated with dendritic cell apoptosis. J Immunol
1996, 157:3577–3586.
43. Murray PJ, Wynn TA: Protective and pathogenic functions of macrophage
subsets. Nat Rev Immunol 2011, 11:723–737.
44. Broichhausen C, Riquelme P, Geissler EK, Hutchinson JA: Regulatory
macrophages as therapeutic targets and therapeutic agents in solid
organ transplantation. Curr Opin Organ Transplant 2012, 17:332–342.
45. Boros P, Ochando JC, Chen SH, Bromberg JS: Myeloid-derived suppressor
cells: natural regulators for transplant tolerance. Hum Immunol 2010,
71:1061–1066.
46. Barnes MJ, Powrie F: Regulatory T cells reinforce intestinal homeostasis.
Immunity 2009, 31:401–411.
47. Day YJ, Huang L, Ye H, Linden J, Okusa MD: Renal ischemia-reperfusion
injury and adenosine 2A receptor-mediated tissue protection: role of
macrophages. Am J Physiol Renal Physiol 2005, 288:F722–F731.
48. Jang HS, Kim J, Park YK, Park KM: Infiltrated macrophages contribute to
recovery after ischemic injury but not to ischemic preconditioning in
kidneys. Transplantation 2008, 85:447–455.
49. Gabrilovich DI, Nagaraj S: Myeloid-derived suppressor cells as regulators
of the immune system. Nat Rev Immunol 2009, 9:162–174.50. Obermajer N: Generation of myeloid-derived suppressor cells using
prostaglandin E2. Transplantation Research 2012, 1:15 doi:10.1186/2047-
1440-1-15.
51. Garcia MR, Ledgerwood L, Yang Y, Xu J, Lal G, Burrell B, Ma G,
Hashimoto D, Li Y, Boros P, et al: Monocytic suppressive cells
mediate cardiovascular transplantation tolerance in mice. J Clin
Invest 2010, 120:2486–2496.
52. Divito SJ, Wang Z, Shufesky WJ, Liu Q, Tkacheva OA, Montecalvo A, Erdos G,
Larregina AT, Morelli AE: Endogenous dendritic cells mediate the effects
of intravenously injected therapeutic immunosuppressive dendritic cells
in transplantation. Blood 2010, 116:2694–2705.
53. Lan YY, Wang Z, Raimondi G, Wu W, Colvin BL, De CA, Thomson AW:
“Alternatively activated” dendritic cells preferentially secrete IL-10,
expand Foxp3+ CD4+ T cells, and induce long-term organ allograft
survival in combination with CTLA4-Ig. J Immunol 2006, 177:5868–5877.
54. Beriou G, Peche H, Guillonneau C, Merieau E, Cuturi MC: Donor-specific
allograft tolerance by administration of recipient-derived immature
dendritic cells and suboptimal immunosuppression. Transplantation 2005,
79:969–972.
55. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N: Antigen-
specific inhibition of effector T cell function in humans after injection of
immature dendritic cells. J Exp Med 2001, 193:233–238.
56. Hutchinson JA, Govert F, Riquelme P, Brasen JH, Brem-Exner BG, Matthai M,
Schulze M, Renders L, Kunzendorf U, Geissler EK, et al: Administration of
donor-derived transplant acceptance-inducing cells to the recipients of
renal transplants from deceased donors is technically feasible. Clin
Transplant 2009, 23:140–145.
57. Hutchinson JA, Roelen D, Riquelme P, Brem-Exner BG, Witzke O,
Philipp T, Matthai M, Govert F, Claas FH, Westphal E, et al:
Preoperative treatment of a presensitized kidney transplant
recipient with donor-derived transplant acceptance-inducing cells.
Transpl Int 2008, 21:808–813.
58. Warnecke G, Hutchinson JA, Riquelme P, Kruse B, Thissen S, Avsar M,
Zehle G, Steinkamp T, Peters C, Baumann R, et al: Postoperative
intravenous infusion of donor-derived transplant acceptance-
inducing cells as an adjunct immunosuppressive therapy in a
porcine pulmonary allograft model. Transpl Int 2009, 22:332–341.
59. Tiurbe G, Matuschek A, Kammerer U, Schneider M, Thiede A, Ulrichs K, Otto C:
Inhibitory effects of rat bone marrow-derived dendritic cells on naive and
alloantigen-specific CD4+ T cells: a comparison between dendritic cells
generated with GM-CSF plus IL-4 and dendritic cells generated with GM-CSF
plus IL-10. BMC Res Notes 2009, 2:12.
60. Chou HS, Hsieh CC, Charles R, Wang L, Wagner T, Fung JJ, Qian S, Lu LL:
Myeloid-derived suppressor cells protect islet transplants by B7-H1
mediated enhancement of T regulatory cells. Transplantation 2012,
93:272–282.
61. Kidney D: Improving Global Outcomes (KDIGO) Transplant Work Group.
KDIGO clinical practice guideline for the care of kidney transplant
recipients. Am J Transplant 2009, 9(Suppl 3):S1–S155.
62. Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P, Chapman
S, Craciun L, Sergeant R, Brouard S, et al: Development of a cross-platform
biomarker signature to detect renal transplant tolerance in humans.
J Clin Invest 2010, 120:1848–1861.
63. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A,
Margreiter R, Hugo C, Grinyo JM, Frei U, et al: Reduced exposure to
calcineurin inhibitors in renal transplantation. N Engl J Med 2007,
357:2562–2575.
64. Ekberg H, Mamelok RD, Pearson TC, Vincenti F, Tedesco-Silva H,
Daloze P: The challenge of achieving target drug concentrations in
clinical trials: experience from the Symphony study. Transplantation
2009, 87:1360–1366.
65. Shapiro R, Jordan ML, Basu A, Scantlebury V, Potdar S, Tan HP, Gray EA,
Randhawa PS, Murase N, Zeevi A, et al: Kidney transplantation under a
tolerogenic regimen of recipient pretreatment and low-dose
postoperative immunosuppression with subsequent weaning. Ann Surg
2003, 238:520–525.
66. Tan HP, Kaczorowski D, Basu A, McCauley J, Marcos A, Donaldson J,
Unruh M, Randhawa P, Zeevi A, Shapiro R: Steroid-free tacrolimus
monotherapy after pretransplantation thymoglobulin or Campath
and laparoscopy in living donor renal transplantation. Transplant
Proc 2005, 37:4235–4240.
Riquelme et al. Transplantation Research 2012, 1:17 Page 14 of 14
http://www.transplantationresearch.com/content/1/1/1767. Tan HP, Donaldson J, Basu A, Unruh M, Randhawa P, Sharma V,
Morgan C, McCauley J, Wu C, Shah N, et al: Two hundred living
donor kidney transplantations under alemtuzumab induction and
tacrolimus monotherapy: 3-year follow-up. Am J Transplant 2009,
9:355–366.
68. Margreiter R, Klempnauer J, Neuhaus P, Muehlbacher F, Boesmueller C,
Calne RY: Alemtuzumab (Campath-1 H) and tacrolimus monotherapy
after renal transplantation: results of a prospective randomized trial. Am
J Transplant 2008, 8:1480–1485.
69. Chan K, Taube D, Roufosse C, Cook T, Brookes P, Goodall D, Galliford J,
Cairns T, Dorling A, Duncan N, et al: Kidney transplantation with
minimized maintenance: alemtuzumab induction with tacrolimus
monotherapy-an open label, randomized trial. Transplantation 2011,
92:774–780.
doi:10.1186/2047-1440-1-17
Cite this article as: Riquelme et al.: Alternative approaches to myeloid
suppressor cell therapy in transplantation: comparing regulatory
macrophages to tolerogenic DCs and MDSCs. Transplantation Research
2012 1:17.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
